<DOC>
	<DOCNO>NCT02297425</DOCNO>
	<brief_summary>Phase 1 - open label , multi-center , non-randomized , safety , pharmacokinetic pharmacodynamics dose escalation study PF-06459988 single agent patient advance EGFRm NSCLC ( del 19 , L858R , +/- T790M ) . The result PF-06459988 dose select phase 1 portion undergo series sub-studies fully characterize impact food , antacid CYP3A4 inhibitors/inducers . The PK study addition MTD expansion complete prior initiation Phase 2 . Phase 2 open label , multi-center single-arm study PF-06459988 assessment antitumor activity patient advance EGFRm ( del 19 L858R ) NSCLC T790M .</brief_summary>
	<brief_title>A Study For Patients With EGFRm ( Epidermal Growth Factor Receptor Mutant ) Lung Cancer</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Mitogens</mesh_term>
	<criteria>Evidence histological cytologically confirm diagnosis locally advance metastatic EGFRm ( del19 L858R ) NSCLC resistant standard therapy . Patients must progress treatment EGFR TKI , may also receive line therapy . Tissue available ( formalin fix paraffin embed ( FFPE ) block 10 unstained section ( 5 micron ) Patients must willing participate additional PK study require ( cohort dependent ) ; patient inform PK study require prior consent study participation Adequate Bone Marrow Function ( Complete Blood Count laboratory test result ) Adequate Liver Function ( Laboratory test ) Previously diagnose brain metastasis , unless patient complete treatment recover acute effect radiation therapy surgery prior study registration , discontinue corticosteroid treatment metastasis least 2 week neurologically stable Systemic anticancer therapy within 4 week start study treatment exclude EGFR TKIs . Patients EGFR TKIs must discontinue agent minimum 5 day prior start study drug Hypertension control medication ( 150/100 mmHg despite optimal medical therapy ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2015</verification_date>
	<keyword>NSCLC , Non-Small Cell Lung Cancer , EGFRm , Epidermal Grown Factor Receptor mutation</keyword>
</DOC>